KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Equity Income: 2020-2023

Historic Equity Income for BeOne Medicines (ONC) over the last 4 years, with Dec 2023 value amounting to -$16.2 million.

  • BeOne Medicines' Equity Income rose 29.29% to -$3.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$16.2 million, marking a year-over-year increase of 26.25%. This contributed to the annual value of -$16.2 million for FY2023, which is 26.25% up from last year.
  • Per BeOne Medicines' latest filing, its Equity Income stood at -$16.2 million for FY2023, which was up 26.25% from -$22.0 million recorded in FY2022.
  • BeOne Medicines' 5-year Equity Income high stood at $11.8 million for FY2020, and its period low was -$22.0 million during FY2022.
  • Its 3-year average for Equity Income is -$10.2 million, with a median of -$16.2 million in 2023.
  • As far as peak fluctuations go, BeOne Medicines' Equity Income plummeted by 388.21% in 2022, and later increased by 26.25% in 2023.
  • Over the past 4 years, BeOne Medicines' Equity Income (Yearly) stood at $11.8 million in 2020, then crashed by 35.46% to $7.6 million in 2021, then tumbled by 388.21% to -$22.0 million in 2022, then climbed by 26.25% to -$16.2 million in 2023.